Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Coya Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Coya Therapeutics' CEO'su Howard Berman, Jan2020 tarihinde atandı, in görev süresi 4.75 yıldır. in toplam yıllık tazminatı $ 1.32M olup, şirket hissesi ve opsiyonları dahil olmak üzere 44% maaş ve 56% ikramiyelerden oluşmaktadır. şirketin hisselerinin 6.24% ine doğrudan sahiptir ve bu hisseler $ 6.12M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.1 yıl ve 3.3 yıldır.

Anahtar bilgiler

Howard Berman

İcra Kurulu Başkanı

US$1.3m

Toplam tazminat

CEO maaş yüzdesi	44.0%
CEO görev süresi	4.8yrs
CEO sahipliği	6.2%
Yönetim ortalama görev süresi	2.1yrs
Yönetim Kurulu ortalama görev süresi	3.3yrs

Son yönetim güncellemeleri

Recent updates

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Mar 26

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Feb 13

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Jan 13

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Sep 06

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

May 17

CEO Tazminat Analizi

Howard Berman'un ücretlendirmesi Coya Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$10m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$1m	US$580k	-US$8m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$13m
Mar 31 2023	n/a	n/a	-US$13m
Dec 31 2022	US$598k	US$413k	-US$12m
Sep 30 2022	n/a	n/a	-US$11m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$390k	US$300k	-US$5m

Tazminat ve Piyasa: Howard 'nin toplam tazminatı ($USD 1.32M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 677.23K ).

Tazminat ve Kazançlar: Howard şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Howard Berman (50 yo)

4.8yrs

Görev süresi

US$1,317,200

Tazminat

Dr. Howard Berman Ph D., has been the Chairman and Chief Executive Officer of Coya Therapeutics, Inc. since 2020. Dr. Berman gained corporate experience with increasing responsibilities and positions as a...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Howard Berman	Chairman & CEO	4.8yrs	US$1.32m	6.24% $ 6.3m
Fred Grossman	President & Chief Medical Officer	1.3yrs	US$862.61k	0% $ 0
David Snyder	CFO & COO	2.6yrs	US$947.89k	0.046% $ 46.1k
Gregory MacMichael	Chief Technical Officer	2.9yrs	Veri yok	Veri yok
Michelle Frazier	Senior Vice President of Regulatory Affairs	1.3yrs	Veri yok	Veri yok
Aaron Thome	Head of Neuroinflammation Platform	no data	Veri yok	Veri yok
Arun Swaminathan	Chief Business Development Officer	1.6yrs	Veri yok	Veri yok

2.1yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim: COYA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Howard Berman	Chairman & CEO	4.8yrs	US$1.32m	6.24% $ 6.3m
Dov Goldstein	Independent Director	3.6yrs	US$63.75k	0.066% $ 65.9k
Stanley Appel	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Lawrence Steinman	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Malcolm Brenner	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Ann Lee	Independent Director	3.3yrs	US$52.50k	0.15% $ 148.1k
Hideki Garren	Independent Director	3.3yrs	US$55.00k	0.013% $ 13.2k
Merit Cudkowicz	Clinical Advisor	1.3yrs	Veri yok	Veri yok
Dieter Weinand	Independent Director	1.2yrs	US$44.16k	Veri yok
Anabella Villalobos	Independent Director	3.4yrs	US$53.75k	0.066% $ 65.9k
Shimon Sakaguchi	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Clive Svendsen	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: COYA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.3 yıldır).

Coya Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Coya Therapeutics, Inc. Announces CEO Changes, Effective November 1, 2024

Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024

Wilbur Ross Joins Coya Therapeutics' Board

Coya Therapeutics, Inc. Appoints Dieter Weinand to Its Board of Directors

Coya Therapeutics, Inc. Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor

Coya Therapeutics, Inc. Announces Management Changes, Effective July 17, 2023

Recent updates

Consensus EPS estimates fall by 10%

New minor risk - Share price stability

Coya Therapeutics, Inc. Announces CEO Changes, Effective November 1, 2024

Consensus revenue estimates fall by 24%

Coya Therapeutics, Inc. Submits an Investigational New Drug Application

Consensus revenue estimates fall by 44%

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

New major risk - Shareholder dilution

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

Consensus revenue estimates increase by 64%, EPS downgraded

Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Consensus revenue estimates increase by 100%

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Coya Therapeutics, Inc. Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of Coya 302 for Treatment of Amyotrophic Lateral Sclerosis

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Wilbur Ross Joins Coya Therapeutics' Board

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis

New minor risk - Share price stability

Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting

Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Coya Therapeutics, Inc. Reports the Publication of a Research Article Entitled “Immunological, Oxidative, and Structural Factors and Their Responses T Lymphocyte Therapy in Amyotrophic Lateral Sclerosis”

Coya Therapeutics, Inc. Appoints Dieter Weinand to Its Board of Directors

New major risk - Financial position

Coya Therapeutics, Inc. Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor

Coya Therapeutics Reports Additional Proof-Of-Concept Clinical Biomarker Data in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. Announces Management Changes, Effective July 17, 2023

Coya Therapeutics, Inc. to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Appoints Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs

Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer's Disease (AD)

Coya Therapeutics, Inc. Announces Appointment of Dr. Guillaume Dorothée to Scientific Advisory Board

Coya Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Coya Therapeutics, Inc. Reports Results from an Open-Label Proof-Of-Concept Clinical Study for COYA 301 in patients with AD. Results of the study

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. has completed an IPO.

High number of new and inexperienced directors

Coya Therapeutics, Inc. has completed an IPO.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş